{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T10:51:31Z","timestamp":1677235891173},"reference-count":19,"publisher":"The Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,7,1]]},"abstract":"<jats:p>Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency is characterized by a defect in cortisol and aldosterone secretion and adrenal hyperandrogenism. Current treatment is to provide adequate glucocorticoid and mineralocorticoid substitution to prevent adrenal crises and to suppress excess adrenal androgen secretion. Satisfactory adrenocortical suppression often requires supraphysiological doses of hydrocortisone, which may produce an unacceptable degree of hypercortisolism. A new four-drug treatment regimen of flutamide, testolactone, reduced hydrocortisone dose, and 9\u03b1-fludrocortisone has been shown to achieve normal growth and development after 2 yr of therapy and may, therefore, represent a potential alternative approach to the treatment of children with classic congenital adrenal hyperplasia.<\/jats:p>\n               <jats:p>We investigated the effect of flutamide and testolactone, and flutamide alone, on cortisol clearance by performing clearance studies twice in 13 children (6 males and 7 females; age range, 7.0\u201314.5 yr) with classic 21-hydroxylase deficiency. All studies were conducted at least 3 months after institution of the four-drug treatment regimen. In eight patients (group 1), the first cortisol clearance study was performed on the four-drug regimen, and the second study was performed after a 48-h washout period off flutamide and testolactone. In five patients (group 2), the first study was conducted 1 wk after discontinuation of testolactone and while patients were receiving flutamide, hydrocortisone and 9\u03b1-fludrocortisone, and the second study was performed after a 48-h washout period off flutamide. Oral hydrocortisone was held on the day of the clearance studies, and all patients received a continuous infusion of hydrocortisone (0.6 mg\/m2\u00b7h) from 1800 h to 0200 h, with cortisol concentrations measured once hourly. In addition, an in vitro study was conducted to exclude the possibility of an analytical interference of flutamide, 2-hydroxyflutamide, and testolactone with the serum cortisol immunoassay.<\/jats:p>\n               <jats:p>Total body cortisol clearance was significantly lower during treatment with the four-drug regimen than during treatment with hydrocortisone and 9\u03b1-fludrocortisone (153.5 \u00b1 26.8 vs.355.4 \u00b1 65.8 ml\/min; P = 0.001). Similar results were obtained comparing flutamide, hydrocortisone, and 9\u03b1-fludrocortisone therapy to hydrocortisone and 9\u03b1-fludrocortisone therapy (155.8 \u00b1 26.5 vs. 281.8 \u00b1 96.2 ml\/min; P = 0.037). The in vitro study indicated that an interference with the serum cortisol immunoassay was unlikely.<\/jats:p>\n               <jats:p>These findings indicate that the addition of flutamide and testolactone to the treatment regimen of hydrocortisone and 9\u03b1-fludrocortisone decreases cortisol clearance in patients with classic 21-hydroxylase deficiency, and this effect seems to be due to flutamide. Glucocorticoid replacement doses should be reduced when flutamide is added to the treatment regimen of patients receiving hydrocortisone.<\/jats:p>","DOI":"10.1210\/jcem.87.7.8652","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T17:08:23Z","timestamp":1389200903000},"page":"3197-3200","source":"Crossref","is-referenced-by-count":4,"title":["Flutamide Decreases Cortisol Clearance in Patients with Congenital Adrenal Hyperplasia"],"prefix":"10.1210","volume":"87","author":[{"given":"Evangelia","family":"Charmandari","sequence":"first","affiliation":[{"name":"Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development (E.C., M.F.K., D.P.M.), Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim A.","family":"Calis","sequence":"additional","affiliation":[{"name":"Clinical Center Pharmacy Department (K.A.C., M.R.M., A.R.), National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret F.","family":"Keil","sequence":"additional","affiliation":[{"name":"Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development (E.C., M.F.K., D.P.M.), Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam R.","family":"Mohassel","sequence":"additional","affiliation":[{"name":"Clinical Center Pharmacy Department (K.A.C., M.R.M., A.R.), National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Remaley","sequence":"additional","affiliation":[{"name":"Clinical Center Pharmacy Department (K.A.C., M.R.M., A.R.), National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah P.","family":"Merke","sequence":"additional","affiliation":[{"name":"Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development (E.C., M.F.K., D.P.M.), Maryland 20892"},{"name":"The Warren Grant Magnuson Clinical Center (D.P.M.), Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071621353000900_R1","first-page":"245","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.","volume":"21","author":"White","year":"2000","journal-title":"Endocr Rev"},{"key":"2020071621353000900_R2","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1056\/NEJM199012273232605","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.","volume":"323","author":"Cutler Jr","year":"1990","journal-title":"N Engl J Med"},{"key":"2020071621353000900_R3","first-page":"3180","article-title":"The use of adrenalectomy as a treatment for congenital adrenal hyperplasia.","volume":"81","author":"Van Wyk","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621353000900_R4","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.1997.03540370063038","article-title":"New approaches to the treatment of congenital adrenal hyperplasia.","volume":"277","author":"Merke","year":"1997","journal-title":"JAMA"},{"key":"2020071621353000900_R5","first-page":"3535","article-title":"A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia.","volume":"81","author":"Laue","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621353000900_R6","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1210\/jcem.85.3.6462","article-title":"Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia.","volume":"85","author":"Merke","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621353000900_R7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2265.1999.00818.x","article-title":"Effect of carbenoxolone on the plasma renin activity and hypothalamic-pituitary-adrenal axis in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.","volume":"51","author":"Irony","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071621353000900_R8","volume-title":"Clinical pharmacokinetics: concepts and applications, ed 3","author":"Rowland","year":"1995"},{"key":"2020071621353000900_R9","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1210\/jcem.86.6.7522","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty.","volume":"86","author":"Charmandari","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621353000900_R10","first-page":"349","article-title":"Steroid catabolism and urinary excretion","author":"Gower","year":"1984","journal-title":"In: Makin HLJ, ed. Biochemistry of steroid hormones. Oxford: Blackwell Science Ltd.;"},{"key":"2020071621353000900_R11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0039-128X(90)90087-R","article-title":"Human hepatic cortisol reductase activities: enzymatic properties and substrate specificities of cytosolic cortisol \u03944-5\u03b2-reductase and dihydrocortisol-3\u03b1-oxidoreductase(s).","volume":"55","author":"Iyer","year":"1990","journal-title":"Steroids"},{"key":"2020071621353000900_R12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2265.1996.716535.x","article-title":"11\u03b2-Hydroxysteroid dehydrogenase: implications for clinical medicine.","volume":"44","author":"Stewart","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071621353000900_R13","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0960-0760(92)90297-V","article-title":"Cortisol metabolism by human liver in vitro\u2014I. Metabolite identification and inter-individual variability.","volume":"43","author":"Abel","year":"1992","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2020071621353000900_R14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1210\/jcem-47-4-788","article-title":"Effect of flutamide on cortisol metabolism.","volume":"47","author":"Fukushima","year":"1978","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621353000900_R15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0039-128X(80)90103-8","article-title":"Further studies on the effect of flutamide on cortisol metabolism.","volume":"35","author":"Fukushima","year":"1980","journal-title":"Steroids"},{"key":"2020071621353000900_R16","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1210\/jcem-45-6-1224","article-title":"The effect of flutamide on testosterone metabolism and the plasma levels of androgens and gonadotropins.","volume":"45","author":"Hellman","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621353000900_R17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1210\/jcem-49-3-467","article-title":"Effect of flutamide on estradiol metabolism.","volume":"49","author":"Zumoff","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071621353000900_R18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0889-8529(08)70022-7","article-title":"New ideas for medical treatment of congenital adrenal hyperplasia.","volume":"30","author":"Merke","year":"2001","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2020071621353000900_R19","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0889-8529(05)70285-1","article-title":"Congenital adrenal hyperplasia.","volume":"26","author":"Pang","year":"1997","journal-title":"Endocrinol Metab Clin North Am"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/87\/7\/3197\/9156792\/jcem3197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/87\/7\/3197\/9156792\/jcem3197.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T09:19:30Z","timestamp":1594977570000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/87\/7\/3197\/2846860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7,1]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2002,7,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jcem.87.7.8652","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7,1]]}}}